Advanced in Chromosome 8p Deletion

Dirk N. Reinhardt

Essen, NW, DE 
Advanced in Chromosome 8p Deletion
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Dirk Reinhardt practices in Essen, Germany. Mr. Reinhardt is rated as an Advanced expert by MediFind in the treatment of Chromosome 8p Deletion. His top areas of expertise are Acute Megakaryoblastic Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 264 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Chromosome 8p Deletion.

Gender
Male

Locations

Essen, NW, Germany
Other Locations
Germany
Muenster, NW 48149, Germany
Heidelberg, BW, Germany
Hannover, NI 30625, Germany
Kiel, SH, Germany
Duisburg, NW, Germany
Berlin, BE, Germany
Wuerzburg, BY 97074, Germany
Ulm, BW, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2

264 Total Publications

Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
Journal: European journal of haematology
Published: May 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Reinhardt's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile